Ascentage Pharma Group International (OTCPK:ASPHF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ascentage Pharma Group International had a gross margin of 91.98% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ascentage Pharma Group International Gross Margin % Related Terms
Ascentage Pharma Group International Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Gross Margin % Chart
ASPHF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Ascentage Pharma Group International's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ascentage Pharma Group International (ASPHF) has a Gross Margin % of 91.98% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Ascentage Pharma Group International and its competitors. This is near median its historical median of 88.80. Over the past decade, Ascentage Pharma Group International's Gross Margin % has ranged from 84.21 to 97.03. According to the industry distribution chart, Ascentage Pharma Group International ranks #103 out of 738 companies in the Biotechnology industry, placing it in the top 14%.
Is Ascentage Pharma Group International's Gross Margin % too high?
Ascentage Pharma Group International's current Gross Margin % of 91.98% is near median its 10-year median of 88.80. Over the past 10 years, this metric has ranged from a low of 84.21 to a high of 97.03. The Biotechnology industry median Gross Margin % is 60.94. Ascentage Pharma Group International's value of 91.98% is 50.9% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #103 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #103 out of 738 companies for Gross Margin %. This places Ascentage Pharma Group International in the top 14% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.94. Ascentage Pharma Group International's value of 91.98% is 50.9% above this benchmark. Historically, Ascentage Pharma Group International's own Gross Margin % has ranged from 84.21 to 97.03 over the past decade. While the company's 10-year median is 88.80 vs. the industry median of 60.94, Ascentage Pharma Group International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Gross Margin % of 91.98% is 50.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Gross Margin % is 91.98%, which is near median its own 10-year median of 88.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Gross Margin % is 91.98%, which is near median its 10-year median of 88.80 and 50.9% above the Biotechnology industry median of 60.94. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Gross Margin % is 91.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Gross Margin %: 91.98% (near median its 10-year median of 88.80)
GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
Industry Position: 50.9% above the Biotechnology median (#103 of 738)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score
Get the complete analysis for ASPHF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
